| Issue |
Section |
Title |
File |
| Vol 9, No 2 (2007) |
Articles |
Sravnitel'noe issledovanie opredeleniya NER2-statusa raka molochnoy zhelezy metodami immunogistokhimii i in situ gibridizatsii |
|
| Vol 11, No 2 (2009) |
Articles |
Sravnitel'noe issledovanie opredeleniya HER2-statusa raka molochnoy zhelezy metodami immunogistokhimii i in situ gibridizatsii |
|
| Vol 15, No 2 (2013) |
Articles |
Prognostic value of p53 expression in patients with stage I breast cancer |
|
| Vol 16, No 2 (2014) |
Articles |
The results of Epidemiological HER2 screening program in patients with breast cancer in 2013 |
|
| Vol 16, No 4 (2014) |
Articles |
Tumor biology or adjuvant systemic therapy: what determines the risk of recurrence in breast cancer stage I? |
|
| Vol 17, No 1 (2015) |
Articles |
Immunological heterogeneity of stage I breast cancer:biological, population-based and prognostic value (international cooperation experience) |
|
| Vol 17, No 2 (2015) |
Articles |
The role and assessment of morphological regression after neoadjuvant therapy in breast cancer patients |
|
| Vol 17, No 3 (2015) |
Articles |
The results of Epidemiological HER2 screening program in patients with breast cancer in 2014 |
|
| Vol 18, No 3 (2016) |
Articles |
The results of epidemiological screening program of HER2 status in patients with breast cancer in the federal districts of the Russian Federation in 2015 |
(Rus)
|
| Vol 14, No 1 (2012) |
Articles |
Evolyutsiya ad\"yuvantnoy lekarstvennoyterapii «rannego» raka molochnoyzhelezy (mnogotsentrovoeissledovanie) |
|
| Vol 14, No 1 (2012) |
Articles |
HER2-testirovanie metodamiimmunogistokhimii, fluorestsentnoy(FISH) i khromogennoy (SISH) in situgibridizatsii pri rake zheludkai pishchevodno-zheludochnogo perekhoda |
|
| Vol 20, No 4 (2018) |
Articles |
Quality control of immunohistochemical analyzes in Russia: yesterday, today, tomorrow |
(Rus)
|
